Drug intelligence / Profile preview

Anti-BCMA-CAR-transduced T cells (Southwest Hospital)

Development stage
Unknown
Lead developer
Southwest Hospital
Modality
CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration
Intravenous
01

Overview

This is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Southwest Hospital in China. It targets the B-cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), which is preferentially expressed on mature B lymphocytes and malignant plasma cells. The therapy involves the genetic modification of a patient's own T cells to express a CAR that recognizes BCMA, enabling the immune system to specifically identify and eliminate malignant B cells. It is primarily being evaluated as a treatment for relapsed or refractory B-cell malignancies, including multiple myeloma, B-cell leukemia, and B-cell lymphoma, and is specifically investigated as a potential rescue therapy for patients who have relapsed after CD19-targeted CAR-T treatments.

Other names
BCMA-targeted CAR-T cellsAnti-BCMA-CAR-TAnti-BCMA-CAR-transduced T cells
02

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on Anti-BCMA-CAR-transduced T cells (Southwest Hospital).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anti-BCMA-CAR-transduced T cells (Southwest Hospital).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call